Abstract: Background and introduction: Lung cancer is a prevalent and deadly disease globally. Non-small cell lung cancer (NSCLC) is the most common subtype, comprising 85% of cases. Case report: A 65-year-old male ex-smoker presented to our facility with a nocturnal cough. Various investigations revealed that he had metastatic NSCLC, for which he underwent chemotherapy with cisplatin and gemcitabine, followed by immunotherapy with Nivolumab. He achieved a complete response to the therapy and has remained free from recurrence for over 7 years since the initial diagnosis. Discussion and Conclusions: The treatment of metastatic NSCLC remains a significant therapeutic challenge, but the implementation of new therapeutic techniques has expanded the possibilities of achieving complete and durable eradication of the disease.
A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report / De Intinis, Claudia; Izzo, Paolo; Codacci-Pisanelli, Massimo; Izzo, Luciano; Messineo, Daniela; Sibio, Simone; Campagnol, Monica; Lai, Silvia; Molle, Marcello; Izzo, Sara. - In: CURRENT ONCOLOGY. - ISSN 1198-0052. - 31(2024), pp. 723-732. [10.3390/curroncol31020053]
A Rare Case of Complete-Immunotherapy-Responsive Metastatic Non-Small Cell Lung Cancer with Long Lasting Progression-Free Survival: A Case Report
Claudia De Intinis
;Massimo Codacci-Pisanelli;Luciano Izzo;Daniela Messineo;Simone Sibio;Silvia Lai;Sara Izzo
2024
Abstract
Abstract: Background and introduction: Lung cancer is a prevalent and deadly disease globally. Non-small cell lung cancer (NSCLC) is the most common subtype, comprising 85% of cases. Case report: A 65-year-old male ex-smoker presented to our facility with a nocturnal cough. Various investigations revealed that he had metastatic NSCLC, for which he underwent chemotherapy with cisplatin and gemcitabine, followed by immunotherapy with Nivolumab. He achieved a complete response to the therapy and has remained free from recurrence for over 7 years since the initial diagnosis. Discussion and Conclusions: The treatment of metastatic NSCLC remains a significant therapeutic challenge, but the implementation of new therapeutic techniques has expanded the possibilities of achieving complete and durable eradication of the disease.File | Dimensione | Formato | |
---|---|---|---|
2024 A Rare Case curroncol-31-00053.pdf
accesso aperto
Note: De Intinis_A Rare Case_2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.47 MB
Formato
Adobe PDF
|
1.47 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.